The utility of anti-SOX2 antibodies for cancer prediction in patients with paraneoplastic neurological disorders
Antibodies to SOXB1 proteins in patients with paraneoplastic disorders are associated with small-cell lung cancer (SCLC), particularly in Lambert-Eaton myasthenic syndrome (LEMS). We aimed to establish if SOX2 antibodies could be used to identify SCLC and other tumours found in a range of paraneoplastic disorders and controls. SOX2 antibodies were detectable in 61% of patients with LEMS-SCLC, and in other paraneoplastic disorders, such as opsoclonus-myoclonus and paraneoplastic cerebellar degeneration, only when there was an underlying SCLC. SOX2 antibodies are specific (>90%) markers for SCLC, but are rarely found in patients with other tumours, whether neurological symptoms are present or not.
|Keywords||Antibodies, Lambert-Eaton myasthenic syndrome, Paraneoplastic, Small-cell lung cancer, SOX2|
|Persistent URL||dx.doi.org/10.1016/j.jneuroim.2018.11.003, hdl.handle.net/1765/112181|
|Journal||Journal of Neuroimmunology|
Maddison, P. (Paul), Titulaer, M.J, Verschuuren, J.J, Gozzard, P. (Paul), Lang, B. (Bethan), Irani, S.R. (Sarosh R.), … Chapman, C.J. (Caroline J.). (2019). The utility of anti-SOX2 antibodies for cancer prediction in patients with paraneoplastic neurological disorders. Journal of Neuroimmunology, 326, 14–18. doi:10.1016/j.jneuroim.2018.11.003